Mark Talamonti to Carcinoma, Pancreatic Ductal
This is a "connection" page, showing publications Mark Talamonti has written about Carcinoma, Pancreatic Ductal.
Connection Strength
2.992
-
Postoperative venous thromboembolism and mortality in patients with pancreatic surgery. J Surg Oncol. 2019 Sep; 120(3):494-500.
Score: 0.636
-
Outcomes after pancreatectomy for intraductal papillary mucinous neoplasms of the pancreas: an institutional experience. Surgery. 2007 Oct; 142(4):529-34; discussion 534-7.
Score: 0.282
-
Extended postoperative thromboprophylaxis after pancreatic resection for pancreatic cancer is associated with decreased risk of venous thromboembolism in the minimally invasive approach. J Surg Oncol. 2023 Mar; 127(3):413-425.
Score: 0.201
-
Does adjuvant radiation provide any survival benefit after an R1 resections for pancreatic cancer? Surgery. 2018 05; 163(5):1047-1052.
Score: 0.144
-
The extent of vascular resection is associated with perioperative outcome in patients undergoing pancreaticoduodenectomy. HPB (Oxford). 2018 02; 20(2):140-146.
Score: 0.143
-
Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study. J Surg Oncol. 2018 Mar; 117(3):354-362.
Score: 0.142
-
Laparoscopic Distal Pancreatectomy for Cancer Provides Oncologic Outcomes and Overall Survival Identical to Open Distal Pancreatectomy. J Gastrointest Surg. 2017 Oct; 21(10):1620-1625.
Score: 0.140
-
Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience. Ann Surg Oncol. 2017 Sep; 24(9):2770-2776.
Score: 0.138
-
A Multi-institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy. Ann Surg. 2016 Oct; 264(4):640-9.
Score: 0.132
-
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
Score: 0.131
-
The Learning Curve Is Surmountable: In Reply to Fong and colleagues. J Am Coll Surg. 2016 Feb; 222(2):210-1.
Score: 0.126
-
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015 Oct; 47(10):1168-78.
Score: 0.122
-
Early National Experience with Laparoscopic Pancreaticoduodenectomy for Ductal Adenocarcinoma: A Comparison of Laparoscopic Pancreaticoduodenectomy and Open Pancreaticoduodenectomy from the National Cancer Data Base. J Am Coll Surg. 2015 Jul; 221(1):175-84.
Score: 0.119
-
The laparoscopic approach to distal pancreatectomy for ductal adenocarcinoma results in shorter lengths of stay without compromising oncologic outcomes. Am J Surg. 2015 Mar; 209(3):557-63.
Score: 0.116
-
Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut. 2012 Oct; 61(10):1454-64.
Score: 0.095
-
A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med. 2010 Jul 13; 7(7):e1000307.
Score: 0.086
-
Mucinous nonneoplastic cyst of the pancreas: apomucin phenotype distinguishes this entity from intraductal papillary mucinous neoplasm. Hum Pathol. 2010 Apr; 41(4):513-21.
Score: 0.082
-
Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol. 2009 Feb 01; 99(2):119-22.
Score: 0.077
-
Risk factors for complications in patients undergoing pancreaticoduodenectomy: A NSQIP analysis with propensity score matching. J Surg Oncol. 2020 Aug; 122(2):183-194.
Score: 0.042
-
Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg. 2008 Dec; 12(12):2078-86.
Score: 0.019
-
Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta. Mod Pathol. 2008 Sep; 21(9):1075-83.
Score: 0.019